Low HIV Testing Rate and Its Correlates Among Male People Who Inject Drugs in Iran

Background: Iran has a concentrated HIV epidemic among people who inject drugs (PWID). Low HIV testing uptake could contribute to the significant number HIV-infected PWID, who go undiagnosed. This study aims to assess HIV testing uptake and its correlates among PWID in Iran. Methods: Data was collected through a national cross-sectional bio-behavioral study in 2010. Adult male HIV-negative PWID were included in the current analysis. All estimates were adjusted for the clustering effect of the sampling sites. Multivariable logistic regression was used to examine the correlates of recent HIV testing and adjusted odds ratios (AOR) were reported. Results: Out of the 2146 eligible PWID for this study, 49.8% reported having ever tested for HIV. However, only 24.9% had tested in the previous year and received their test results. Around 65.2% of PWID knew an HIV testing site. In the multivariable analysis, knowing an HIV testing site (AOR= 13.9; P-value<0.001), ≥24 years of age (AOR= 3.30; P-value= 0.027), and mult ip le incarcerations (AOR= 1.71; P-value<0.001) were positively, and a monthly income of ≥65 US dollar (AOR= 0.23; P-value=0.009) was negatively associated with having been tested and received the results. Conclusion: Despite the availability of free HIV counselling and testing for PWID in Iran, only one-fourth of adult male PWID had been tested for HIV and received their results. Implementing policies and strategies to normalize routine HIV testing among PWID are crucial steps to help curb the epidemic among Iranian PWID.

[1]  Ruchika Mishra,et al.  The Case , 2016, Cambridge Quarterly of Healthcare Ethics.

[2]  Mohammad Reza Baneshi,et al.  National population size estimation of illicit drug users through the network scale-up method in 2013 in Iran. , 2016, The International journal on drug policy.

[3]  A. Mirzazadeh,et al.  Correlates of HIV Testing among Female Sex Workers in Iran: Findings of a National Bio-Behavioural Surveillance Survey , 2016, PloS one.

[4]  M. Abdollahi,et al.  Drug use treatment and harm reduction programs in Iran: A unique model of health in the most populated Persian Gulf country. , 2015, Asian journal of psychiatry.

[5]  A. Vallely,et al.  Factors impacting HIV testing: a review – perspectives from Australia, Canada, and the UK , 2015, AIDS care.

[6]  K. Dolan,et al.  Opioid use, treatment and harm reduction services: the first report from the Persian Gulf region , 2014 .

[7]  G. Rutherford,et al.  Access to harm reduction programs among persons who inject drugs: findings from a respondent-driven sampling survey in Tehran, Iran. , 2014, The International journal on drug policy.

[8]  A. Haghdoost,et al.  HIV prevalence and risk behaviours among people who inject drugs in Iran: the 2010 National Surveillance Survey , 2013, Sexually Transmitted Infections.

[9]  D. Hamer,et al.  HIV/AIDS-Related Knowledge and Behaviors Among Most-at-Risk Populations in Vietnam , 2012, The open AIDS journal.

[10]  M. Kall,et al.  Late HIV diagnosis in Europe: A call for increased testing and awareness among general practitioners , 2012, The European journal of general practice.

[11]  M. Vazirian,et al.  Transition to injection amongst opioid users in Iran: implications for harm reduction. , 2012, The International journal on drug policy.

[12]  A. Rahimi-Movaghar,et al.  HIV prevalence amongst injecting drug users in Iran: a systematic review of studies conducted during the decade 1998-2007. , 2012, The International journal on drug policy.

[13]  E. Vittinghoff,et al.  Decreases in Community Viral Load Are Accompanied by Reductions in New HIV Infections in San Francisco , 2010, PloS one.

[14]  J. Oliffe,et al.  Youth’s experiences with STI testing in four communities in British Columbia, Canada , 2009, Sexually Transmitted Infections.

[15]  Crime.,et al.  WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users.. , 2009 .

[16]  M. Gouya,et al.  Needle and Syringe Sharing Practices Among Injecting Drug Users in Tehran: A Comparison of Two Neighborhoods, One with and One Without a Needle and Syringe Program , 2010, AIDS and Behavior.

[17]  C. Magis-Rodríguez,et al.  Barriers and missed opportunities to HIV testing among injection drug users in two Mexico--US border cities. , 2008, Drug and alcohol review.

[18]  C. Sabin,et al.  Late Diagnosis of HIV Infection: Epidemiological Features, Consequences and Strategies to Encourage Earlier Testing , 2007, Journal of acquired immune deficiency syndromes.

[19]  M. Claeson,et al.  HIV/AIDS harm reduction in Iran , 2006, The Lancet.

[20]  Evan Wood,et al.  The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic , 2006, The Lancet.

[21]  C. Beyrer,et al.  HIV Voluntary Counseling and Testing and HIV Incidence in Male Injecting Drug Users in Northern Thailand: Evidence of an Urgent Need for HIV Prevention , 2006, Journal of acquired immune deficiency syndromes.

[22]  A. Haghdoust,et al.  ESTIMATING THE TIME TREND OF ADJUSTED INCIDENCE OF OPIOID DEPENDENCY AND MULTIPLE FACTORS RELATED TO THE LAG TIME: BACKWARD CALCULATION METHOD , 2006 .

[23]  M. Claeson,et al.  HIV / AIDS Prevention among Injecting Drug Users : Learning from Harm Reduction in Iran , 2006 .

[24]  M. Trace,et al.  THE RISE OF HARM REDUCTION IN THE , 2005 .

[25]  C. Latkin,et al.  Correlates of HIV Antibody Testing Among a Sample of Injection Drug Users: The Role of Social and Contextual Factors , 2004, AIDS and Behavior.

[26]  W. Miller,et al.  Barriers to asymptomatic screening and other STD services for adolescents and young adults: focus group discussions , 2004, BMC public health.

[27]  J. Fortenberry,et al.  Attitudes about sexual disclosure and perceptions of stigma and shame , 2002, Sexually transmitted infections.

[28]  G. Kenyon.  United Nations General Assembly on HIV/AIDS , 2001 .